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Available online 22 September 2017Acute limb ischaemia is caused by compromised tissue perfusion and requires immediate attention to reduce the
occurrence of secondary complications that could lead to amputation or death. To address this, we have devel-
oped a novel platinum (Pt)-based electrochemical oxygen (O2) device for future applications in clinical monitor-
ing of peripheral tissue ischaemia. The effect of integrating a Pt pseudo-reference electrode into theO2 devicewas
investigated in vitro with an optimum reduction potential of−0.80 V. A non-significant (p = 0.11) decrease in
sensitivity was recorded when compared against an established Pt-based O2 sensor operating at−0.65 V. Fur-
thermore, a biocompatible clinical sensor (ClinOX) was designed, demonstrating excellent linearity (R2 =
0.99) and sensitivity (1.41± 0.02 nA μM−1) for O2 detection. Significant rapid decreases in the O2 current during
in vivo ischaemic insults in rodent limbs were reported for Pt-Pt (p b 0.001) and ClinOX (p b 0.01) and for ClinOX
(p b 0.001) in porcine limbs. Ex vivo sensocompatibility investigations identified no significant difference (p =
0.08) in sensitivity values over 14 days of exposure to tissue homogenate. The Pt-Pt based O2 design demonstrat-
ed high sensitivity for tissue ischaemia detection and thus warrants future clinical investigation.








Oxygen (O2) is of critical importance in a myriad of physiological
processes. Thus, timely and accurate monitoring techniques are essen-
tial to assist clinicians with potential lifesaving decisions. Historically,
oxygenation has been monitored subjectively by clinical assessment
due to the paucity of techniques to accurately evaluate precise tissue ox-
ygen levels. Over the past 60 years, measuring andmonitoringmethods
have been developed to quantify oxygen supply and, more recently, to
continuously assess the oxygenation of blood and tissues both
invasively and noninvasively [1,2]. Currently, the traditional gold stan-
dard methods of O2 measurement performed in hospitals are pulse ox-
imetry (PulsOx) and arterial blood gas analysis (ABG). PulsOx was
developed in 1972 by Japanese engineers [3] who noted the pulsatile
components of the absorbance of red and infrared light transmitted
through tissue were related to arterial haemoglobin saturation [4].
However, this method is an indirect marker of tissue perfusion and
functionality is lost in the absence of a pulse wave [5]. ABG machines
revolutionised critical patient care following their introduction in the
late 1950's [2] as blood samples could be analysed for a range ofparameters including blood gases, haemocrit, electrolytes, metabolites,
and co-oximetry. However, significant drawbacks include the time lag
associated with single point measurements and the deterioration of
blood samples, culminating in false readings and misdiagnoses. More-
over, both methods are unsuitable for continuous real-time O2 mea-
surements in peripheral tissue due to their reliance on vascular factors.
No gold standard currently exists for the early diagnosis of trauma-
or thrombosis-induced complications. Acute limb ischaemia (ALI), a
common cause of morbidity and mortality, is defined as a restriction
in blood flow to the extremities that causes a shortage of theO2 and glu-
cose required for cellular metabolism. ALI pathophysiologies require
timely surgical intervention to restore blood perfusion to the impacted
tissue. For example, acute compartment syndrome (ACS) is a very seri-
ous condition that results from increasedpressurewithin amuscle com-
partment following trauma, which can lead to muscle and nerve
damage and compromised blood flow unless detected early. When the
intramuscular tissue pressure becomes higher than the blood pressure
within capillaries, the capillaries collapse and disrupt blood flow, O2,
and nutrient delivery to nerve and muscle cells that renders them isch-
aemic [6–9]. Compartment syndrome is a time-critical medical emer-
gency, in which irreversible nerve and muscle damage can occur after
just six hours of increased intra-compartmental pressure. Recovery
from tissue ischaemia complications is largely dependent on tissue
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capillaries, and venules, which are responsible for tissue oxygenation
and, ultimately, tissue (and organ) health [11].
Blood perfusion is commonly assessed by non-invasive Laser Dopp-
ler Imaging (LDI), which measures blood flow through backscattering a
laser beam that interacts withmoving red blood cells [12,13]. While the
non-invasive nature of LDI is highly desirable, it suffers from a lack of
standardisation, poor temporal resolution, and can only penetrate tissue
to a maximum depth of 10 mm [10]. More recently, near infrared spec-
troscopy (NIRS) has demonstrated excellent clinical utility that has fa-
cilitated clinical diagnoses [14–16]. NIRS utilises light waves ranging
from 680 to 800 nm tomeasure tissue O2 saturation by light absorption
of oxygenated and deoxygenated haemoglobin [17] with increased tis-
sue penetration up to a depth of 15mm [5]. However, this indirectmea-
sure of tissue oxygenation with varied predictability for any clear effect
magnitude or ischemic threshold has limited the clinical applicability of
NIRS [18]. Furthermore, the probe has depth measurement restrictions
in that superficial muscle readily absorbs the light, while deep muscles
are difficult to isolate [18].
Molecular O2 electrochemical detection was first reported by Clark
approximately 60 years ago with a gold or platinum (Pt) working elec-
trode and an Ag/AgCl reference electrode in a KCL electrolyte encased
within an O2 permeable membrane [19,20]. Over the years, Clark-type
electrodes have become the gold standard for measuring levels of O2
in tissue [21]. In fact, the aforementioned ABG machine utilises a Clark
O2 electrode. In addition the Licox® O2 probe, which is also based on
the Clark design, is the only invasive O2 system currently approved for
clinical use, particularly for cerebral O2 monitoring [22]. The continuous
real-timemonitoringwith the Licox®O2 probe in traumatic brain injury
patients has gained significant traction in the last decade [21,23]. More-
over, a number of recent studies have reported applicationswithin skel-
etal muscle [24–26] and the feasibility of continuous tissue O2
measurements has been demonstrated in humans following tibia frac-
ture [27]. Hansen et al. confirmed that the level of muscle O2 responds
rapidly to ischemia and correlates with biochemical markers of muscle
ischemia, including ATP and pH [25]. The Licox®O2 probewas designed
with brain monitoring as its core application and the development of a
more suitable intramuscular sensor to directly measure O2 levels would
represent a key advancement in diagnosing tissue ischemia complica-
tions, such as compartment syndrome. The onset of post-trauma com-
partment syndrome symptoms can range from 2 h to 6 days, and
delayed diagnoses could result in permanent nerve damage, contrac-
tures, or amputation, requiring extensive follow-up consultations and
procedures for otherwise healthy patients. Due to the severe health im-
plications of acute ischaemia, the development of a medical device to
detect early onset in “at risk”patients bymeasuringmuscle oxygenation
following a high impact trauma would be advantageous and extremely
beneficial for clinicians.
Different electrode substrates have been utilised for the electro-
chemical detection of O2, including noble metals such as Pt [21,28]
and Au [29,30] and carbon-based materials comprising glassy carbon
[30], carbon fibre (CFE) [31,32], and carbon paste (CPE) [28,33]. CFEs
are advantageous as tissue damage is minimal following in vivo implan-
tation; however, variations in the detection of O2 concentrations can re-
sult from electrode placement relative to blood vessels and
metabolically active sites [28]. Furthermore, their fragility renders
them unsuitable for clinical monitoring. On the other hand, CPEs dem-
onstrate excellent long-term stability once implanted [33], however,
there are biocompatibility concerns related to the gradual leeching of
oil and paste upon contact with lipids in tissue [34]. Pt is the preferred
choice of electrode substrate in the majority of electrochemical O2 sen-
sors due to its excellent ability to electrocatalyse the reduction ofmolec-
ular O2 through a single step, four-electron process to H2O [21,28].
Furthermore, its biocompatibility makes it an ideal candidate for acute
and chronic implantation in the human body [35]. It is a major compo-
nent ofmanymedical devices in useworldwide for assessing conditionssuch as heart disease, stroke, neurological disorders, and chronic pain
[35]. This work describes the in vitro development of a novel and im-
plantable Pt-based electrochemical sensor (ClinOX) for monitoring pe-
ripheral tissue O2 using a sensing component suitable for future
patient monitoring. The in vitro performance of this ClinOX design was
investigated and compared against a pre-clinical Pt design. The efficacy
of the different designs at measuring peripheral tissue ischaemia was
investigated in small and large animal models. Finally, the effect of
long-term exposure to muscle tissue homogenate on Pt sensitivity
was investigated ex vivo. The work described demonstrates the feasibil-
ity of a Pt-based electrochemical device for the continuous real-time
monitoring of peripheral tissue O2 in humans in the future.
2. Materials and methods
2.1. Chemicals and solutions
All reagents used in phosphate buffered saline (PBS), i.e. sodium
chloride (NaCl), sodiumhydroxide (NaOH) and sodiumhydrogen phos-
phate (NaH2PO4), and clinical interference studies, i.e. acetaminophen
and acetylsalicyclic acid, were purchased from Sigma Aldrich Chemical
Co. (Dublin, Ireland).
2.2. Electrode manufacture
The electrodes used in this study were manufactures as follows:
2.2.1. Platinum (Pt) disk working electrodes (O2 electrode)
Pt disk electrodes weremade from Teflon®-insulated Platinum/Irid-
ium (Pt/Ir 90%/10%) wire (127 μm bare diameter, 203 μm coated diam-
eter (5 T), Science Products GmbH, Hofheim, Germany). The electrodes
were 5 cm in length andwere prepared by carefully cutting 2mmof the
Teflon® insulation from one end of the wire. A gold electrical contact
(in vitro: Fine Science Tools GmbH, Heidelberg, Germany; in vivo:
Bilaney Consultants, Sevenoaks, UK) was soldered for rigidity to the
bare end to enable connection with electrochemical instrumentation.
A fresh surfacewas cut at the opposite end of thewire to generate an ac-
tive disk surface for electrochemical reactions.
2.2.2. Pt cylinder electrodes
Pt cylinder electrodes were manufactured in a similar manner, ex-
cept that a cylinder surface was prepared by removing 5 mm of the
Teflon® insulation from the active end of the wire. These cylinder elec-
trodes served as pseudo-reference electrodes (PRE) and auxiliary elec-
trodes for Pt-Pt O2 sensors.
2.2.3. Pt-SCE O2 sensor
This sensor design consisted of a Pt disk O2 electrode, a saturated cal-
omel electrode (SCE) as the reference electrode, and a Pt rod that acted
as the auxiliary electrode.
2.2.4. Pt-Pt O2 sensor
The sensor design comprised a Pt disk O2 electrode, a Pt cylinder PRE,
and a Pt cylinder auxiliary electrode.
2.2.5. Clinical O2 sensor (ClinOX)
The sensor was manufactured in a two-step process as represented
schematically in Figure SM2. A nylon tipwas constructed using injection
moulding (Clada Medical Devices, Galway, Ireland). A channel was in-
corporated into this nylon tip to facilitate a 1–2 mm length of 500 μm
bare Pt rod (Advent Research Materials, Oxford, UK). A 25 cm length
of Teflon® insulated 100 μm copper wire (Goodfellow, Huntingdon,
UK) was soldered to the Pt rod following removal of 2 mm Teflon® in-
sulation at one end. This construct was then fed through the channel
and the Pt rod was secured using epoxy with 0.1–0.2 mm protruding
from the nylon tip and the copper wire from the opposite end. A scalpel
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was ensured with polishing paper. Electrical contact was confirmed be-
tween the Pt disk and the exposed copper wire.
A 20 cm length of 1 mm diameter extruded biocompatible PeBax®
polymer sheath (Clada Medical Devices, Galway, Ireland) was used in
the construction of the sensor shaft. Briefly, two holes were created ca.
0.25 cm and 0.50 cm from one end of the sheath. Two lengths (25 cm)
of Teflon® insulated copper wire, with ca. 2 mm of metal exposed at
both ends, were fed through each of the pierced holes in the sheath to
the opposite end with ca. 5 cm excess outside the end of the sheath.
Two Pt marker bands (1.1 mm inner diameter, Fort WayneMetals, Cas-
tlebar, Ireland) were swaged over each of the pierced holes and pro-
truding wires, ensuring no copper wire remained exposed outside the
sheath. Electrical connection was confirmed between the marker band
and the respective copper wire. The copper wire was fed from the pre-
viously prepared nylon tip/wire construct down through the sheath,
and the tipwas glued in place at the shaft end The internal sheath cavity
encompassing the marker bands and moulded nylon tip was filled with
biocompatible glue (MasterBond, New Jersey, USA), to prevent fluid
entry. More glue was incorporated into the junction between themark-
er band and sheath to prevent fluid entry, taking care not to cover the
marker band.
Finally, a stress relief component was glued to the opposite sheath
end with protruding lengths of exposed copper wire. The respective
components of an electrical connector (Farnell Element 14, Leeds, UK
or Fischer Connectors, Edinburgh, UK) were placed around this sheath
end and each exposed copper wire was soldered into corresponding
pins on their respective connectors. The wires were tested for electrical
contact between the marker bands, Pt disk, and connector pins. Once
electrical contact was confirmed, the respective connector was carefully
screwed in place and electrical connection was confirmed for the final
device.
2.3. In vitro calibrations
All calibrations were performed in a standard three-electrode glass
electrochemical cell containing 20mL PBS. The PBSwas purged with ei-
ther N2 gas (BOC Ireland), atmospheric air (RENA air-pump) or O2 gas
(BOC Ireland) for 20 min and the appropriate gaseous atmosphere
was maintained for 15 min over the cell solution during quiescent re-
cordings. The concentrations of solution O2 were taken as 0 μM (N2-sat-
urated), 240 μM (air-saturated) and 1200 μM (O2-saturated) [28].
2.3.1. Cyclic voltammetry (CV) studies #1
Pt-SCEO2 sensors (see Section 2.2.3)were cycled (0.20V→−0.80 V,
100 mVsec−1) in N2, air, and O2 saturated PBS.
2.3.2. Cyclic voltammetry (CV) studies #2
Pt-Pt O2 sensors (see Section 2.2.4) were cycled (0.20 V → −1.0 V,
100 mVsec−1) in N2, air and O2 saturated PBS.
2.3.3. O2 sensor calibration #1
Pt-SCE O2 sensors were calibrated as described above using constant
potential amperometry (CPA) at−0.65 V vs. SCE.
2.3.4. O2 sensor calibration #2 (Pt-Pt device)
Pt-Pt O2 sensors were calibrated as described above using CPA at
−0.65 V vs. Pt and −0.80 V vs. Pt.
2.3.5. O2 sensor calibration #3 (ClinOX device)
ClinOX sensors (see Section 2.2.5) were calibrated as described
above using CPA at−0.80 V vs. Pt.
2.3.6. Clinical interference studies on Pt-Pt O2 sensor
Further interference studies were performed on Pt-Pt O2 sensors
using acetaminophen and acetylsalicyclic acid. A physiologicallyrelevant concentration (500 μM) of both interferents was added to N2
saturated PBS and the current response was recorded over a five-
minute period. The maximum current at the end of this period was
compared against the pre-injection baseline level.
2.4. Open circuit potential (OCP) investigations
OCP investigations were performed in PBS using a voltmeter (Iso-
Tech, Southport, UK). The voltage difference was measured between
the Pt working electrode and the respective reference electrode. Fur-
thermore, the stability of the PREwith respect to the SCEwas also deter-
mined with respect to time. The voltage was recorded every 10 s over a
20-min period and the data plotted. In addition, longer term studies in-
volved a voltage point recorded every 10 min over an 80-min period.
2.5. Ex vivo sensocompatibility calibrations
Different sets of Pt-Pt O2 sensors were stored in homogenised por-
cine tissue at 4 °C for 1, 3, 7, or 14 days. The devices were then rinsed
in distilled H2O and an O2 calibration over a 0–1200 μM concentration
range was performed using CPA.
2.6. In vivo experimental and hind limb ischaemia protocol
2.6.1. Rodent experiments
MaleWistar rats (Charles River, UK, 400–600 g) were housedwith a
maximum of three per cage in a temperature (17–23 °C), humidity, and
light controlled (12 h light, 12 h dark cycle) environment at Maynooth
University. Food and water were available ad libitum. The subjects
were allowed to acclimatise for at least one week prior to surgery. For
in vivo experiment 1, the Pt-Pt O2 sensors were implanted into left
and right hind limbs (see Fig. 3A and SM1) through a 21G hypodermic
needle. For in vivo experiment 2, ClinOX devices were implanted into
left and right hind limbs through a 14G hypodermic needle. Once im-
planted, the hypodermic needles were retracted from the tissue. The
rats were anaesthetised with Isoflurane anaesthesia (Abbott Laborato-
ries, Dublin, Ireland) in the supine position with the anaesthesia mask
fixed tightly around the nose. The subject was kept on a heating pad
for the duration of the recording to prevent hypothermia. A sterilised
tourniquet was placed around the subject's limb (greater trochanter)
in close proximity to the body to facilitate occlusion of the blood supply.
Ischaemia was induced by pulling the tourniquet as tight as possible,
verified visually by the increasing pallor of the subject's foot, and was
maintained for a 10-min period. Once completed, the tourniquet was
removed and recordings continued for a further 20 min. Subjects were
euthanised upon completion of recordings by intraperitoneal injection
of Euthatal. All experimental procedures were performed at Maynooth
University under license in accordancewith the European Communities
Regulations 2002 (Irish Statutory Instrument 165/2013).
2.6.2. Porcine experiments
Male Landrace pigs (sourced by the Biomedical Research Facility,
Beaumont Hospital, Dublin, Ireland, 45–75 kg) were housed, with a
maximum of four per room, in a temperature (17–23 °C), humidity,
and light controlled (12 h light, 12 h dark cycle) environment at the Bio-
medical Research Facility, Beaumont Hospital, Dublin. Food and water
were available ad libitum. The subjects were allowed to acclimatise for
at least 48 h prior to surgery. For in vivo experiment 3, ClinOX devices
were implanted into left and right limbs through a 14G hypodermic
needle. Once implanted, the hypodermic needles were retracted from
the tissue. The limb was extended and held in position for the duration
of the recording using a retort stand and clamp (see Figure SM3). The
pigs were anaesthetised by trained staff at the research facility using
standard operating procedures and placed in the supine position for
the duration of the recording. Subjects were kept under isoflurane an-
aesthesia throughout. A sterilised tourniquet (SP Services, Shropshire,
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to facilitate occlusion of the blood supply. Ischaemia was induced by
twisting the tourniquet bar as tight as possible and fixing it into a
locking mechanism. The ischaemic insult was maintained for 10 min.
Once completed, the tourniquet bar was removed from the locking
mechanism and loosened. The recordings continued for a further
20 min. Subjects were euthanised upon completion of recordings by
trained staff at the research facility. All experimental procedures were
performed at the Biomedical Research Facility, BeaumontHospital, Dub-
lin under license in accordancewith the EuropeanCommunities Regula-
tions 2002 (Irish Statutory Instrument 165/2013).
2.7. In vivo amperometric recordings
All recordings were carried out with the subjects under general an-
aesthesia. For Experiment 1, all electrodes were connected via corre-
sponding gold electrical contacts to a bespoke three-core cable, and
soldered to contacts in a jack plug adaptor (Farnell Element 14, Leeds,
UK), which was connected to the respective potentiostat (described in
Section 2.8). For Experiment 2 and 3, the ClinOX device was connected
via jack plug connection and Fischer Connector, respectively, which
were then connected to their respective potentiostats (described in
Section 2.8). The desired reduction potential was applied to the respec-
tive O2 devices and the currents were allowed to stabilise for 10–15min
prior to inducing ischaemic insult. In total, each recording was per-
formed for 45 min.
2.8. Instrumentation, software and data acquisition
In vitro CPA and CV experiments were performed using a low-noise
potentiostat (ACM Instruments, Cumbria, UK) and converted using an
A/D converter (PowerLab, ADInstruments, Oxford, UK) running on a
Dell computer. The CPA and CV signals were recorded using LabChart
software (v8, ADInstruments, Oxford, UK) and eChem software
(v2.1.16, eDAQ Ltd., Sydney, Australia), respectively. All data analysis
was performed using GraphPad Prism v5 (GraphPad Software Inc., San
Diego, CA, USA).
For in vivo experiments 1 and 2, the amperometric O2 current was
detected using a prototype single channel potentiostat (Bluebridge
Technologies, Dublin, Ireland) and converted using an A/D converter
(PowerLab). The digital signal was then recorded using LabChart soft-
ware v8 running on a Dell Laptop. All data analysis was performed
using GraphPad Prism v5. For in vivo experiment 3, the amperometric
O2 current was detected using a rechargeable battery-operated single
channel potentiostat with an in-built A/D converter (Bluebridge Tech-
nologies, Dublin, Ireland). This clinically viable hardware unit provides
the added benefit of removing the direct electrical contact between de-
vice and patient, significantly increasing benefit-to-risk rationale. This
potentiostat is ISO 13485 compliant and is a battery-operated version
of the prototype utilised during in vivo experiments 1 and 2 (see
Figure SM5)with telemetric functionality. The digital signal was record-
ed using a custom designed IEC 62304 compliant IOS App (Bluebridge
Technologies, Dublin, Ireland) running on an Apple iPad (see
Figure SM5). All data was compiled in Microsoft Excel and all data anal-
ysis was performed using GraphPad Prism v5 (GraphPad Software Inc.,
CA, USA).
All in vivo figures presented had baseline levels normalised to 100%
to illustrate the overall change in current as a % of the pre-ischemia
baseline level. This removes both inter-electrode and inter-animal vari-
ability by ensuring that the presented current changes are representa-
tive of the data from all animals used in each study. Reported in vivo
concentration changes are based on in vitro pre-calibration curves, i.e.
average slope/sensitivity recorded for respective O2 sensor designs.
For clarity, all in vivo currents have been transformed to positive values.
For in vitro and in vivo investigations, significant differences were calcu-
lated using the Student's t-test for paired or unpaired observations,where appropriate. For ex vivo sensocompatability investigations, the
significant differences observed were calculated using one-way
ANOVAs with a Bonferroni post-hoc test. Two-tailed levels of signifi-
cance were set at p b 0.05. n values are representative of the number
of ischaemic insults/number of animals.
3. Results
3.1. In vitro investigations comparing Pt-Pt and Pt-SCE electrochemical
designs
Fig. 1A and B show the CV investigations of the O2 reduction charac-
teristics of Pt-Pt and Pt-SCE designs in air and O2 saturated PBS. It should
be noted that the potential window for the Pt-SCE design was restricted
to −0.80 V to mitigate interference from the generation of H2, which is
initiated at this potential. It is apparent from the voltammograms that
the maximum currents for both Pt designs are comparable; however,
the reductive peak is pushed to a more negative potential and more de-
fined, albeit broader, in the Pt-Pt design. The foot of the reductive wave
for the Pt-SCE in both air-saturated and O2-saturated PBS commenced
at −0.20 V and the maximum peak between −0.25 V and −0.30 V,
which is comparable to that reported previously for the same design
[28]. In contrast, the reductive foot for the Pt-Pt design commenced at
−0.40 V for both O2 concentrations, while the reductive peak occurred
at−0.55V in air-saturated and−0.60V inO2-saturated PBS. Amore neg-
ative potential infers that discrete equilibrium potentials exist between
working and reference electrodes in both configurations. This was con-
firmed by OCP measurements performed between the Pt working elec-
trodes and the respective reference electrodes, i.e. SCE and PRE. Fig. 1C
illustrates the OCP measured between the Pt electrode and SCE over a
20-min period. The OCP measured at 20 min (0.22 V) demonstrated a
slight drift over this period, but the potential stabilised (see Fig. 1C
inset) when investigated over a longer 80-min period. A similar trend
was observed in the OCPmeasured between the Pt electrode and PRE, al-
beit at a lower potential (0.09 V). A slight drift in OCPwas recorded over a
20-min period (Fig. 1D), but this stabilised towards the end of the 80-min
recording. The difference in OCP (Δ 0.13 V) between configurations lends
support to the variations observed between reduction waves in Fig. 1A
and B. Furthermore, when OCP measurements were undertaken with
PRE vs. SCE, a voltage difference of 0.21 V was identified after 20 min. A
similar trend in voltage drift is clearly evident in Fig. 1E, thus supporting
a stable drift in equilibrium potential between both configurations.
It was therefore decided to apply the previously published−0.65 V
reduction potential [28] and amore negative−0.80 V reduction poten-
tial to the Pt-Pt configuration for subsequent CPA investigations. Amax-
imum potential of −0.80 V vs. Pt was chosen to alleviate concerns
surrounding the unfavourable generation of H2 in vivo, which occurs
through the electrolysis of water at potentials close to−0.80 V vs. SCE
(data not shown). An initial O2 calibration over the concentration
range 0–1200 μM was performed on the Pt-SCE design at −0.65 V vs.
SCE, which demonstrated excellent linearity (R2 = 0.99) and good sen-
sitivity (0.79 ± 0.07 nA μM−1, n= 8, Table 1). However, an O2 calibra-
tion on the Pt-Pt design at −0.65 V vs. Pt demonstrated a significantly
reduced (p b 0.001) sensitivity (0.37 ± 0.05 nA μM−1, n= 8) and line-
arity (R2 = 0.98). This was not entirely unexpected based on the volt-
ammograms presented in Fig. 1A and B. The larger negative potential
of −0.80 V vs. Pt was applied to the Pt-Pt electrode configuration and
an improvement in sensitivity (0.64 ± 0.06 nA μM−1, n = 8, Table 1)
and linearity (R2 = 0.99) was recorded. This increased sensitivity was
significantly different (p b 0.01) when compared to Pt-Pt at −0.65 V
vs. Pt, but there was no significant difference (p = 0.11) when com-
pared against the Pt-SCE design at−0.65 V vs. SCE (see Fig. 2A and B).
Furthermore, the limit of detection (LOD)was comparable across all de-
sign configurations:−0.65 V vs. SCE, 0.23 ± 0.04 μM (n=8);−0.65 V
vs. Pt, 0.26 ± 0.08 μM (n= 8);−0.80 V vs. Pt, 0.30 ± 0.02 μM (n= 8).
Table 1 compares the respective in vitro characteristics of these
Fig. 1. Cyclic voltammetry (CV) plots comparing platinum platinum (Pt-Pt) O2 sensor (solid line) and Pt-saturated calomel electrode (Pt-SCE) O2 sensor (dashed line) in (A) air saturated
and (B) oxygen (O2) saturated phosphate buffered saline (PBS). 20-min open circuit potential (OCP)measurements performed on (C) Pt-SCE, (D) Pt-Pt and (E) pseudo reference electrode
(PRE) vs. SCE in PBS. Insets: OCP stability measurement performed over an 80-min period.
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−0.80 V configurations demonstrate comparable signal stability, am-
perometric currents were recorded overnight for both configurations
under ambient air conditions (21% O2). It is apparent from Fig. 2C thatTable 1





Pt-SCE (−0.65 V vs. SCE)
(n = 8)
0.79 ± 0.07 62.2 ±
Pt-Pt (−0.65 V vs. Pt)
(n = 8)
0.37 ± 0.05 29.5 ±
Pt-Pt (−0.80 V vs. Pt)
(n = 8)
0.64 ± 0.06 50.4 ±
ClinOX (−0.80 V vs. Pt)
(n = 10)
1.41 ± 0.02 7.2 ±both signals (Pt-SCE, black trace and Pt-Pt, blue trace) stabilisedwith re-
spect to time, thus corroborating OCP measurements illustrated in Fig.
1C-E. Taken collectively, these findings confirm that applying −0.80 V






5.3 0.23 ± 0.04 0.99
4.3 0.26 ± 0.08 0.98
4.6 0.30 ± 0.02 0.99
0.1 0.19 ± 0.06 0.99
Fig. 2. (A) Current-concentration profiles (n=8) for (0–1200 μM)O2 calibration on Pt-Pt O2 sensor at−0.65 V (black trace) and−0.80 V (blue trace) and Pt-SCE O2 sensor (red trace) at
−0.65 V. (B) O2 sensitivity comparisons for Pt-Pt O2 sensor at −0.65 V (black column) and −0.80 V (blue column) and Pt-SCE O2 sensor (red column) at−0.65 V. Data presented as
nAμM−1 ± SEM (n = 8). * denotes level of significance. (C) Stability of amperometric current (n = 4) overnight for Pt-SCE at −0.65 V (black trace) and Pt-Pt at −0.80 V (blue trace)
in ambient air (21% O2) conditions (Inset: stability traces with shortened y axis scale). (D) Current-concentration profile (n = 10) for 0–1200 μM O2 calibration on ClinOX O2 sensor at
−0.80 V vs. Pt. Average current response (n = 4) of Pt-Pt O2 sensor to addition of (E) 500 μM aliquot of acetylsalicyclic acid and (F) 500 μM aliquot of acetaminophen to N2 saturated
PBS at−0.80 V vs. Pt. Mean current response represented by black trace, % error represented by grey trace.
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and acetylsalicyclic acid—two electroactive interferents with a high
probability of being present in patient tissue. Calibrations were per-
formed at −0.80 V vs. Pt by adding 500 μM aliquots of interferent to
N2-saturated PBS and the current response recorded over a five-
minute period. An initial increase in current response was observed fol-
lowing the addition of the respective interferents (Fig. 2E and F), but the
effect was transient and the current response returned to pre-injections
levels within the five-minute period. Specifically, non-significant cur-
rent changes (1.75 ± 0.87 nA, n = 4, p = 0.14 and 0.29 ± 0.31 nA, n
= 4, p = 0.41) were recorded for acetylsalicyclic acid and acetamino-
phen, respectively, compared to pre-injection levels. When comparingthese currents against the O2 currents detected at the Pt-Pt O2 sensors,
these deviations from baseline levels were deemed negligible and likely
attributed to a convective artefact associatedwith the addition of the re-
spective aliquot.
3.2. In vitro comparison of Pt-Pt and novel ClinOX electrochemical designs
A novel electrochemical device suitable for clinical monitoring was
designed based on feedback received from clinical experts. A single im-
plantable device incorporating three Pt electrodeswas constructed as il-
lustrated in Figure SM2 and described in Section 2.2.5. In vitro
calibrations performed on this novel ClinOX sensor (see Fig. 2D) over
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(R2 = 0.99) and sensitivity (1.41 ± 0.02 nA μM−1, n = 10). For direct
sensitivity comparisons between the ClinOX sensor and the Pt-Pt sen-
sor, current densities were calculated to account for the different phys-
ical dimensions of the recording surface areas using the formula,
J ¼ I=A
where ‘J’ refers to the current density of the disk electrode, ‘I’ refers to
the current in nA, and ‘A’ refers the area of the disk electrode in mm2.
The sensitivity of the Pt-Pt device was approximately seven times that
of the ClinOX device: 50.4 ± 4.6 nA mm−2 μM−1, n = 8, R2 = 0.99 vs.
7.2 ± 0.01 nA mm−2 μM−1, n = 10, R2 = 0.99, respectively (Table 1).
Regardless of this discrepancy, the sensitivity of the ClinOX sensor was
more than adequate for physiological measurements. In addition, the
LOD was determined to be 0.19 ± 0.06 μM (n=10), which was an im-
provement on all Pt-Pt devices described in Section 3.1.
3.3. In vivo experiment #1 – measurement of peripheral tissue O2 current
using the Pt-Pt device during acute limb ischaemia in anaesthetised rats
Amperometric O2 currents were recorded from the hind limb of
anaesthetised Wistar rats using the experimental set-up illustrated in
Fig. 3A and SM1. The current was allowed to dissipate over a 10–
15 min period prior to application of the tourniquet, as this time was
suitable (see SM4) for establishing a stable baseline. As illustrated in
Fig. 3B and Table 2, the O2 current decreased significantly (p b 0.001,
see Fig. 3C) by 50.6 ± 5.3 nA (n = 12/6) from a pre-insult baselineFig. 3. (A) Schematic illustrating in vivo experimental set-up for continuous electrochemical dete
loosely around the top of the limb (greater trochanter) prior to insertion of a 21Ghypodermic ne
left implanted in tissue. All three electrodes are connected to a potentiostat for data acquisitio
subsequent reperfusion in the hind limb of an anaesthetised rat. Mean % O2 response repr
baseline current vs. average ischaemic current (p b 0.001) vs. average reperfusion current (p blevel of 90.2 ± 7.3 nA following application of a tourniquet to the hind
limb. The maximum response of the ischaemic insult after 4.6 ±
0.6 min corresponded to a percentage change of 59.1 ± 4.6 from pre-
insult levels. Furthermore, this current change translated into a decrease
in concentration of 79.0± 8.3 μM. The O2 current increased immediate-
ly upon removal of the tourniquet and reperfusion levels reached a
maximum (123.1±10.0 nA) after 4.8±0.7min,whichwas significant-
ly different from the pre-insult baseline (p b 0.001).3.4. In vivo experiment #2 – measurement of peripheral tissue O2 current
using the ClinOX device during acute limb ischaemia in anaesthetised rats
The ClinOX device was implanted through a 14 G needle into the
hind limb of anaesthetised rats using an identical set-up to that detailed
in Figs. 3A and SM3. As previously described, the currentwas allowed to
dissipate over a 10–15min period prior to application of the tourniquet.
Fig. 4A and Table 2 illustrate the effect of the ischaemic insult on the
ClinOX device. Briefly, the O2 current decreased significantly (p b 0.01,
see Fig. 4B) by 105.6 ± 20.1 nA (n = 9/6) from a pre-insult baseline
level of 166.5 ± 21.3 nA following application of the tourniquet. The
maximum response of the ischaemic insult after 4.3 ± 1.1 min
corresponded to a percentage change of 62.8 ± 6.5 from pre-insult
levels. Furthermore, this current change translated into a decrease in
concentration of 74.9 ± 14.2 μM. The O2 current increased immediately
upon removal of the tourniquet and reperfusion levels reached a maxi-
mum (154.6 ± 27.3 nA) after 5.6 ± 1.5 min. However, reperfusion
levels failed to overshoot pre-insult baseline levels (p = 0.51).ction of tissueO2 in the rat hind limb ischaemiamodel. A tourniquet (tiewrap)was placed
edle containing the Pt-Pt O2 sensor configuration.Needle is retracted and electrode tips are
n. (B) Average % O2 response (n = 12/6) Pt-Pt O2 sensor to a 10-min ischemic insult and
esented by black trace, % error represented by grey trace. (C) Comparisons of average
0.001). Data represented as mean current ± SEM. * denotes level of significance.
Table 2
Summary of in vivo amperometric O2 data recorded from both Pt-Pt configurations in rodent and porcine models of acute limb ischaemia.
Baseline (nA) Δ I (nA) Max % response Max I (min) Reperfusion I (nA) Reperfusion (min)
Pt-Pt
(rat, n = 12/6)
90.2 ± 7.3 50.6 ± 5.3 59.1 ± 4.6 4.6 ± 0.6 123.1 ± 10.0 4.8 ± 0.7
ClinOX
(rat, n = 9/6)
166.5 ± 21.3 105.6 ± 20.1 62.8 ± 6.5 4.3 ± 1.1 154.6 ± 27.3 5.6 ± 1.5
ClinOX
(pig, n = 11/6)
128.2 ± 10.8 69.8 ± 10.2 52.5 ± 4.2 3.3 ± 0.9 145.0 ± 20.8 4.9 ± 1.4
Where ‘I’ denotes current.
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during limb ischaemia in anaesthetised pigs
The ClinOX device was implanted through a 14 G needle into the
limb of anaesthetised pigs, as illustrated in Figure SM3. Similar to previ-
ous investigations, the current was allowed to dissipate over a 10-min
period prior to tourniquet application. Fig. 5A and Table 2 illustrateFig. 4. (A) Average % O2 response (n = 9/6) from ClinOX O2 sensor to a 10-min ischemic
insult and subsequent reperfusion in the hind limb of an anaesthetised rat. Mean % O2
response represented by black trace, % error represented by grey trace. (B) Comparisons
of average baseline current vs. average ischaemic current (p b 0.01) vs. average
reperfusion current (p = 0.51). Data represented as mean current ± SEM. * denotes
level of significance.the effect of the ischaemic insult on the ClinOX device. In summary,
the O2 current decreased significantly (p b 0.001, see Fig. 5B) by 69.8
± 10.2 nA (n = 11/6) from a pre-insult baseline level of 128.2 ±
10.8 nA following application of the tourniquet to the hind limb. The
maximum response of the ischaemic insult after 3.3 ± 0.9 min
corresponded to a percentage change of 52.5 ± 4.2 from pre-insult
levels. Furthermore, this current change translated into a decrease in
concentration of 49.5 ± 7.2 μM. The O2 current increased immediately
upon removal of the tourniquet and reperfusion levels reached a maxi-
mum (145.0 ± 20.8 nA) after 4.9 ± 1.4 min. However, an overshoot inFig. 5. (A) Average % O2 response (n=11/6) ClinOXO2 sensor to a 10-min ischemic insult
and subsequent reperfusion in the hind limb of an anaesthetised pig. Mean % O2 response
represented by black trace, % error represented by grey trace. (B) Comparisons of average
baseline current vs. average ischaemic current (p b 0.001) vs. average reperfusion current
(p= 0.38). Data represented as mean current ± SEM. * denotes level of significance.
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insult baseline levels (p = 0.69).
3.6. Ex vivo sensocompatibility studies on Pt-Pt design
The interaction that results from sensor implantation into tissue is
one of the major obstacles for developing viable long-term implantable
sensors. All implanted devices are subject to physiological responses, in-
cluding protein and lipid adsorption. Therefore, it was decided to inves-
tigate the effect of long-term exposure (Day 1–14) of porcine tissue
homogenate on the sensitivity of the Pt-Pt design ex vivo. It is evident
from Fig. 6 that there is a negligible effect of the tissue homogenate
over a 14-day period when compared to non-treated Pt-Pt devices. In
summary, the sensitivities recorded on Day 0 (0.64 ± 0.06 nA μM−1, n
= 8, R2 = 0.99), Day 1 (0.38 ± 0.06 nA μM−1, n = 4, R2 = 0.98), Day
3 (0.49 ± 0.10 nA μM−1, n = 4, R2 = 0.99), Day 7 (0.40 ± 0.08 nA
μM−1, n = 4, R2 = 0.97) and Day 14 (0.45 ± 0.06 nA μM−1, n = 4, R2
= 0.99) demonstrated no significant difference (p = 0.08, one-way
ANOVA), which suggested retained stability following tissue exposure.
Bonferroni post-hoc analysis identified no significant variation in sensi-
tivities across Day 1 and Day 14 (p = 0.84), which is more representa-
tive of the actual effect of tissue exposure on sensor performance
given that there was no exposure to tissue homogenate on Day 0. This
assumption was supported further by unpaired t-tests performed be-
tween individual exposure days. A significant decrease in sensitivity
(p = 0.03) was recorded initially between Day 0 vs. Day 1, which cor-
roborates previous reports using implantable brain sensors [36,37].
However, there were no further significant differences between Day 1
vs. Day 3 (p = 0.54), Day 1 vs. Day 7 (p = 0.95), or Day 1 vs. Day 14
(p = 0.69). This demonstrates the in vivo stability of the Pt-Pt device
over a 14-day exposure period, thus supporting its potential utility for
continuous long-term clinical monitoring.
4. Discussion
Many microelectrode types have been used for the electrochemical
reduction of molecular O2 [28,33,37,38]. Platinum has particularly ex-
cellent electrocatalytic properties that make it an ideal candidate for
O2 reduction [21], which consists of a four-electron reduction to H2O:Fig. 6. Pt-Pt sensitivity values recorded at −0.80 V vs. Pt over 0–1200 μM concentration
range following long-term exposure (0–14 days) to porcine tissue homogenate. Inset:
Day 1–14 porcine tissue statistical analysis. Data presented as nAμM−1 ± SEM.O2 þ 4Hþ þ 4e−→2 H2O
Previous work has demonstrated excellent in vitro characteristics for
Pt-based electrodes, including high sensitivity, interference free signals,
nopHor ion effects, aswell as comparable detection limits and response
times to CPEs [28]. For in vivo recordings, the conventional reference
electrode is typically replaced by a miniature PRE. Therefore, it was im-
perative to investigate the effect of changing reference electrodes on the
O2 reduction potential using cyclic voltammetry. The essential differ-
ence betweenSCE and PRE reference electrodes is a poorly defined equi-
librium potential in PREs between the metal and solution phase [39],
thusmaking it difficult to calculate the exact potential of PREs. However,
Ag-PRE electrodes have demonstrated excellent stability in vivo follow-
ing long-term implantation in the brain of freely moving rats [40–42]
and mice [43]. For our purpose, we chose a Pt-PRE due to its aforemen-
tioned inert biocompatible characteristics. Figs. 1A and B illustrate a
shift in reduction potential to a more negative value, most likely ex-
plained by discrepancies in the equilibrium potential between the Pt
electrode and the respective reference electrodes. This was substantiat-
ed through OCP measurements performed with respect to both elec-
trode configurations. OCP measurements identified an equilibrium
potential variance of 0.13 V between configurations, whichmay explain
the difference in reductivewave potentials observed in Figs. 1A and B. In
addition, OCP investigations illustrate a slight drift in potential with re-
spect to dissipation times in both configurations after ca. 60 min, al-
though greater stabilisation was observed with the Pt-SCE design. In
fact, the overall drift in equilibrium potential in the Pt-Pt design
stabilises with time and would not translate into unpredictable O2 cur-
rent drifts, further supporting the reliability of use in long-term record-
ings. This was substantiated by OCPmeasurements performed between
PRE vs. SCE. Furthermore, when the amperometric O2 current was in-
vestigated in PBS exposed to ambient air (21% O2), both Pt-SCE (at
−0.65 V) and Pt-Pt (at−0.80 V) configurations demonstrated equiva-
lent signal stability over an 18-h period. Collectively, these findings
illustrate the comparable performances of both electrode configura-
tions, thus alleviating concerns regarding PRE incorporation into
the design.
The previously reported −0.65 V and experimentally identified
−0.80 Vwere both applied to the Pt-Pt design during CPA experiments.
A significant difference in sensitivitywas recorded between both poten-
tials, but no significant differences were observed when sensitivities of
the Pt-SCE design at −0.65 V vs. SCE and Pt-Pt design at −0.80 V
were compared. This lends support to the latter being the optimal po-
tential for maximising O2 detection using theminiaturised Pt-Pt design.
Further, in vitro investigations were performed on our novel ClinOX de-
sign to evaluate its performance characteristics over the conventional
O2 calibration range and larger reduction potential with clinical moni-
toring as a target application. In the field of medical devices, platinum's
durability, inertness, and electrical conductivity make it the ideal elec-
trode material for devices ranging from pacemakers, implantable defi-
brillators, neuromodulation devices, and cochlear implants [35]. The
ClinOX device demonstrated excellent linearity and improved sensitiv-
ity on the Pt-Pt design. Table 1 compares the analytical performance of
the respective Pt-Pt and Pt-SCE configurations in terms of key in vitro
parameters, such as LOD, linearity, and current density (J). The latter
permits a sensitivity comparison across varying electrode geometries.
Despite the large disparity between J values, the sensitivity and im-
proved LOD calculated for the ClinOX device make it more than ade-
quate for in vivo monitoring. Similar current densities and LODs have
been reported previously by other groups for the electrochemical detec-
tion of O2 on Pt substrates [21,28]. The selectivity of Pt electrodes for O2
reduction has been demonstrated previously against a myriad of
electroactive interferents found in brain ECF with b1% contribution to
the overall signal detected at 50 μM O2 [28]. The majority of these
interferents are also present in peripheral tissue where O2
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tion, due to the clinical focus of this work, further investigations were
undertaken against acetaminophen (paracetamol) and acetylsalicyclic
acid (aspirin), both of which are likely to be present in patient intersti-
tial fluid. Negligible interference was observed for both electroactive
species, even at anO2 concentration of 0 μM. The absence of O2 signal in-
terference can be attributed in part to the large faradaic currents gener-
ated as a result of O2 detection that mitigate against a myriad of
potential sources of interference.
The efficacy of the Pt-Pt design inmeasuring O2 changeswithin skel-
etal tissuewas subsequently examined by implanting both Pt-Pt config-
uration (Pt-Pt and ClinOX) designs in peripheral tissue and exposing the
limb to acute ischaemia under tourniquet control. Tourniquets are rou-
tinely clinically applied to maintain a bloodless field during surgeries in
the area of the limb distal to the occlusion. Rendering the limb of an an-
imal ischaemic is currently considered to be the most effective method
for simulating the conditions of haemodynamic complications, includ-
ing critical limb ischaemia and compartment syndrome [44]. The rodent
ismost frequently utilisedwith surgical procedures ranging from arteri-
al ligation [44,45], complete excision [46,47], electrocoagulation [46],
and the application of a tourniquet around the limb [48]. Furthermore,
since the targeted application for the ClinOX device was clinical moni-
toring, the larger porcine model was also investigated since it more
closely represents the size and haemodynamics of the human vascular
system [44]. Table 2 provides a summary of the in vivo amperometric
O2 data recorded from both Pt-Pt configurations in rodent and porcine
models of acute limb ischaemia. Both Pt-Pt configurations recorded im-
mediate and significant decreases (ca. 50–60%) in amperometric cur-
rents that demonstrated similarities across subjects when normalised
values were calculated. Since the amperometric O2 current measured
at the sensor surface is a balance between the O2 supplied from the vas-
culature and that utilised by the surrounding tissue [49], we postulate
that the decrease in current is attributed to a reduced blood O2 supply
following tourniquet application, while cellular utilisation remains con-
stant throughout the ischemic insult. Thiswould result in a net decrease
in the O2 current. Furthermore, there was no significant variation in the
maximum response times (p= 0.58, one-way ANOVA, n=6), indicat-
ing that a comparable level of ischaemia was induced followed tourni-
quet application across all Pt-Pt configurations and animal species
investigated. These findings corroborate recent work using non-
invasive imaging in porcine limb that measured an immediate drop in
oxygenated haemoglobin (within the first 10min) after induction of is-
chaemia that continued to decrease over the course of the insult (3–
4 h), albeit at a much slower rate [10]. Their objective was to measure
locomotion recovery and required significantly longer durations of is-
chaemia to achieve this. The principle objective of ourworkwas to dem-
onstrate the feasibility of a novel Pt-Pt electrode configuration for
measuring tissue O2 changes during an ischaemic episode and, as
such, the insult duration was of little significance. Nevertheless, there
are striking similarities between both configurations that strongly sup-
port the validity of our device atmeasuring tissue perfusion. Otherwork
reported that ischaemic insult causes a decrease in glucose concentra-
tion and a concurrent increase in lactate concentration, measured
using microdialysis [48]. The increase in lactate postulates anaerobic
glycolysis in the absence of O2 availability—a finding that was attenuat-
ed following exposure to hyperbaric O2.
Reperfusion following tourniquet release produced variable re-
sponses across Pt-Pt configurations and animal species. The Pt-Pt design
(Fig. 3B and C) resulted in a significant (p b 0.001) overshoot in the re-
duction current following cessation of ischaemia, which corroborates
work described by others [10,48]. Conversely, the ClinOX device (Fig.
4A and B) showed an immediate increase in O2 current upon tourniquet
removal, but no overshoot was observed (p=0.51) when compared to
pre-insult level in the rodent hind limbs. A plausible explantation for
this could be that the form factor of the larger ClinOX device renders it
unsuitable for measurements in rodent limbs since a significantovershoot was reported in the identical animal model using the smaller
Pt-Pt design. It is apparent from Fig. 4A that the reduction current grad-
ually returned to pre-insult levels during reperfusion. However, the dif-
fusion of the analyte to the electrode surface may be hindered by the
geometry or tubular design of the ClinOX device. This hypothesis was
somewhat substantiated during reperfusion recordings in the porcine
model. It is apparent from Fig. 5A that although an overshoot was not
apparent (p = 0.38), the reduction current quickly returned to pre-
insult levels and stabilised. Albeit variable, the reperfusion response re-
corded across all Pt-Pt configurations clearly illustrated an immediate
increase in current during the restoration of blood flow. Intuitively,
this suggests that the reduction current is increasing due to an increase
in the O2 supply from the vasculature upon removal of the tourniquet.
The overshoot in current observed from the Pt-Pt design in rat limb re-
cordings is in line with previous work [10] that reports an overshoot in
oxygenated haemoglobin compared to pre-ischaemic levels. The tran-
sient nature of this overshoot is identical to that observed in Fig. 3B.
This can possibly be explained by an increase in tissue O2 utilisation fol-
lowing the ischaemic episode that eventually returned the current to
stable levels representative of a balanced O2 supply and utilisation.
Sensocompatibility investigations were performed ex vivowhereby
the complete Pt-Pt design of the O2 electrode, PRE, and auxiliary elec-
trode were exposed to homogenised porcine muscle tissue for a speci-
fied duration. Sensocompatibility is a term coined by Wisniewski and
colleagues to describe the effect the bodyhas on an electrochemical sen-
sor [50], and has been reported previously for different sensors [28,51].
The in vivo environment presents a complex chemical milieu that in-
cludes electrode contaminations, such as lipids, proteins, and a tissue
matrix that restricts mass transport to the electrode surface and physi-
ologically reacts to a sensor's presence [36,37,52]. The effect of brain ho-
mogenate on Pt electrodes has been reported previously whereby bare
Pt electrodes demonstrated a decrease in sensitivity after three days of
exposure, though no significant difference was noted when compared
against non-treated electrodes [28]. In our case, a drop in sensitivity
after 24 h of exposure was noted, which illustrated a negligible devia-
tion over the subsequent 14 days. This initial compromise in sensitivity
is to be expected following tissue homogenate contact [37]. The adhe-
sion and proliferation of fouling agents such as proteins and lipids on
all Pt electrodes serve to briefly degrade the device's functionality. Fur-
thermore, the performance of the Pt-Pt O2 device differs little from pre-
vious sensocompatibility studies performed by different groups on
different sensors [50,53,54]. More specifically, the lack of any significant
difference recorded across the actual homogenate exposure days (Day
1–Day 14) signifies a negligible effect of physiological conditions on
the sensor's performance. Collectively, these sensocompatibility results
support the ability of the Pt-Pt configuration to provide reliable and sta-
ble O2 readings in physiological tissue with a minimal contribution, if
any, from signal drifts.
A final consideration is the well-established dependence of O2 sen-
sors, including Clark type electrodes and their miniaturised counter-
parts, on temperature changes in vivo. An estimated deviation of ca.
3% per 1 °C for Pt electrodes has been reported previously, though this
has a negligible impact on brain level recordings due to the highly reg-
ulated cerebral temperature levels [28]. However, temperature changes
associatedwith skeletal tissue ischaemia are expected to bemuch larger
and could potentially interfere with O2 measurements unless compen-
sated for through concurrent temperature monitoring. Since our princi-
ple objective was to demonstrate feasibility of the Pt-Pt configuration at
measuringO2 changes during acute ischaemia, the effect of temperature
on our O2 signal was deemed negligible. The temperature effect of a 10-
min ischaemic insult under tourniquet control in a porcine model was
recorded as b1 °C, but the temperature decreased linearly over a subse-
quent three-hour period with an approximate change of ca. 10 °C [10],
which would have a significant impact on the O2 signal unless compen-
sated for. This is an important consideration when deploying this Pt-Pt
configuration in future models of extremity vascular injury,
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this Pt-Pt O2 configuration would be to prove the concept in a human
clinical study.
5. Conclusion
Wehave described the in vitro development and in vivo validation of
a novel Pt-based electrochemical device that permits the continuous
real-time measurement of peripheral tissue O2. In vitro investigations
determined a significant difference in sensitivities recorded for the pre-
viously reported Pt-SCE design and our novel Pt configuration at
−0.65 V vs. reference electrode. Increasing the reduction potential of
our Pt design to −0.80 V vs. Pt resulted in a significant improvement
in sensitivity that was comparable to the Pt-SCE design. The novel
ClinOX device demonstrated a good linear sensitivity value over the
conventional 0–1200 μM O2 calibration range with the added benefit
of being constructed from biocompatible materials that render it suit-
able for clinical use. The in vivo application of both Pt-Pt configurations
in the hind limb of anaesthetised rats resulted in significant decreases in
O2 currents compared to baseline levels over the course of a 10-min
ischaemic insult. Discrepancies in reperfusion characteristics were re-
ported and attributed to the difference in size and geometries of both
designs in the rodent model. Subsequently, the ClinOX design was de-
ployed in a porcine model of limb ischaemia and a significant decrease
in O2 currents compared to baseline levels was reported. The return of
the O2 current to pre-insult levels during reperfusion supports the abil-
ity of the ClinOX design tomeasure real-time O2 perturbations during a
period of ischaemia in an animal model that closely represents the size
and haemodynamics of the human vascular system. Thework described
within is a prerequisite for the future deployment of this Pt-Pt ClinOX
design in a clinical study of the real-timemeasurement of O2 levels dur-
ing tissue ischaemia.
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